BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization September 27, 2022 BLRX announces self-commercialization strategy (27-Sep-22) (Hebrew) (final).pdf 235.8 KB